Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di fase III per valutare l'inibitore AZD9833+ CDK4/6 in HR+/HER2-MBC con ESR1m rilevabile prima della progressione (SERENA-6) (SERENA-6)

22 settembre 2026 aggiornato da: AstraZeneca

Uno studio di fase III, in doppio cieco, randomizzato per valutare il passaggio a AZD9833 (un SERD orale di nuova generazione) + inibitore CDK4/6 (Palbociclib o Abemaciclib) vs inibitore continuativo dell'aromatasi (letrozolo o anastrozolo) + inibitore CDK4/6 in HR+/ Pazienti HER2-MBC con mutazione rilevabile di ESR1 senza progressione della malattia durante il trattamento con 1 litro con inibitore dell'aromatasi + inibitore CDK4/6- Studio di passaggio precoce guidato da ctDNA

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Panoramica dello studio

Descrizione dettagliata

Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.

This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.

The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.

Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:

  • palbociclib + anastrozole
  • palbociclib + letrozole
  • abemaciclib + anastrozole
  • abemaciclib + letrozole
  • ribociclib + anastrozole
  • ribociclib + letrozole

During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.

In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.

The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.

The researchers also want to know more about how safe AZD9833 is.

The trial participants will be split into 2 groups:

  • Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
  • Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.

Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

315

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Birtinya, Australia, 4575
        • Research Site
      • Darlinghurst, Australia, 2010
        • Research Site
      • Graz, Austria, 8036
        • Research Site
      • Innsbruck, Austria, 6020
        • Research Site
      • Salzburg, Austria, 5020
        • Research Site
      • Vienna, Austria, 1130
        • Research Site
      • Leuven, Belgio, 3000
        • Research Site
      • Liège, Belgio, 4000
        • Research Site
      • Namur, Belgio, 5000
        • Research Site
      • Haskovo, Bulgaria, 6300
        • Research Site
      • Panagyurishte, Bulgaria, 4500
        • Research Site
      • Pleven, Bulgaria, 5804
        • Research Site
      • Plovdiv, Bulgaria, 4004
        • Research Site
      • Sofia, Bulgaria, 1431
        • Research Site
      • Sofia, Bulgaria, 1407
        • Research Site
      • Sofia, Bulgaria, 1527
        • Research Site
      • Sofia, Bulgaria, 1330
        • Research Site
      • Sofia, Bulgaria, 1303
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Research Site
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Research Site
    • Quebec
      • Lévis, Quebec, Canada, G6V 3Z1
        • Research Site
      • Montreal, Quebec, Canada, H2X 0C1
        • Research Site
      • Montreal, Quebec, Canada, H3T 1E2
        • Research Site
      • Montreal, Quebec, Canada, H1T 2M4
        • Research Site
      • Québec, Quebec, Canada, G1S 4L8
        • Research Site
      • Cheonan-si, Corea del Sud, 31151
        • Research Site
      • Daegu, Corea del Sud, 42415
        • Research Site
      • Goyang-si, Corea del Sud, 10408
        • Research Site
      • Seongnam-si, Corea del Sud, 13620
        • Research Site
      • Seongnam-si, Corea del Sud, 463-712
        • Research Site
      • Seoul, Corea del Sud, 02841
        • Research Site
      • Seoul, Corea del Sud, 03080
        • Research Site
      • Seoul, Corea del Sud, 03722
        • Research Site
      • Seoul, Corea del Sud, 05505
        • Research Site
      • Seoul, Corea del Sud, 06273
        • Research Site
      • Seoul, Corea del Sud, 06351
        • Research Site
      • Seoul, Corea del Sud, 06591
        • Research Site
      • Avignon, Francia, 84918
        • Research Site
      • Brest, Francia, 29200
        • Research Site
      • Clermont-Ferrand, Francia, 63050
        • Research Site
      • Dijon, Francia, 21079
        • Research Site
      • Limoges, Francia, 83000
        • Research Site
      • Lorient, Francia, 56322
        • Research Site
      • Lyon, Francia, 69373
        • Research Site
      • Marseille, Francia, 13273
        • Research Site
      • Metz-Tessy, Francia, 74370
        • Research Site
      • Nîmes, Francia, 30029
        • Research Site
      • Paris, Francia, 75248
        • Research Site
      • Rouen, Francia, 76021
        • Research Site
      • Saint-Cloud, Francia, 92210
        • Research Site
      • Saint-Herblain, Francia, 44805
        • Research Site
      • Toulouse, Francia, 31100
        • Research Site
      • Tours, Francia, 37000
        • Research Site
      • Vandœuvre-lès-Nancy, Francia, 54519
        • Research Site
      • Vantoux, Francia, 57070
        • Research Site
      • Villejuif, Francia, 94805
        • Research Site
      • Ansbach, Germania, 91522
        • Research Site
      • Augsburg, Germania, 86156
        • Research Site
      • Bonn, Germania, 53111
        • Research Site
      • Chemnitz, Germania, 09116
        • Research Site
      • Dresden, Germania, 01307
        • Research Site
      • Erlangen, Germania, 91054
        • Research Site
      • Essen, Germania, 45130
        • Research Site
      • Freiburg im Breisgau, Germania, 79110
        • Research Site
      • Hösbach, Germania, 63768
        • Research Site
      • Immenstadt im Allgäu, Germania, 87509
        • Research Site
      • Koblenz, Germania, 56068
        • Research Site
      • Leipzig, Germania, 4103
        • Research Site
      • Mannheim, Germania, 68167
        • Research Site
      • München, Germania, 80634
        • Research Site
      • Paderborn, Germania, 33098
        • Research Site
      • Ratingen, Germania, 40878
        • Research Site
      • Ravensburg, Germania, 88212
        • Research Site
      • Regensburg, Germania, 93053
        • Research Site
      • Stade, Germania, 21680
        • Research Site
      • Tübingen, Germania, 72076
        • Research Site
      • Ulm, Germania, 89075
        • Research Site
      • Chiba, Giappone, 260-8717
        • Research Site
      • Chūōku, Giappone, 104-0045
        • Research Site
      • Hidaka-shi, Giappone, 350-1298
        • Research Site
      • Hirakata-shi, Giappone, 573-1191
        • Research Site
      • Kitaadachi-gun, Giappone, 362-0806
        • Research Site
      • Kumamoto, Giappone, 860-8556
        • Research Site
      • Kōtoku, Giappone, 135-8550
        • Research Site
      • Matsuyama, Giappone, 791-0280
        • Research Site
      • Nagoya, Giappone, 464-8681
        • Research Site
      • Nagoya, Giappone, 467-8602
        • Research Site
      • Niigata, Giappone, 951-8566
        • Research Site
      • Osaka, Giappone, 540-0006
        • Research Site
      • Osaka, Giappone, 541-8567
        • Research Site
      • Ota-shi, Giappone, 373-8550
        • Research Site
      • Sapporo, Giappone, 003-0804
        • Research Site
      • Shinagawa-ku, Giappone, 142-8666
        • Research Site
      • Shinjuku-ku, Giappone, 162-8655
        • Research Site
      • Takasaki-shi, Giappone, 370-0829
        • Research Site
      • Takatsuki-shi, Giappone, 569-8686
        • Research Site
      • Tsukuba, Giappone, 305-8577
        • Research Site
      • Yokohama, Giappone, 241-8515
        • Research Site
      • Beersheba, Israele, 8410101
        • Research Site
      • Haifa, Israele, 3109601
        • Research Site
      • Jerusalem, Israele, 91120
        • Research Site
      • Petah Tikva, Israele, 494142
        • Research Site
      • Ramat Gan, Israele, 5262000
        • Research Site
      • Bergamo, Italia, 24127
        • Research Site
      • Bologna, Italia, 40138
        • Research Site
      • Florence, Italia, 50134
        • Research Site
      • Meldola, Italia, 47014
        • Research Site
      • Milan, Italia, 20141
        • Research Site
      • Milan, Italia, 20132
        • Research Site
      • Misterbianco, Italia, 95045
        • Research Site
      • Naples, Italia, 80131
        • Research Site
      • Padova, Italia, 35128
        • Research Site
      • Roma, Italia, 00168
        • Research Site
      • Rozzano, Italia, 20089
        • Research Site
      • Drammen, Norvegia, 3004
        • Research Site
      • Oslo, Norvegia, 0450
        • Research Site
      • Bydgoszcz, Polonia, 85-796
        • Research Site
      • Gdynia, Polonia, 81-519
        • Research Site
      • Koszalin, Polonia, 75-581
        • Research Site
      • Lodz, Polonia, 90-302
        • Research Site
      • Poznan, Polonia, 60-693
        • Research Site
      • Rzeszów, Polonia, 35-001
        • Research Site
      • Tomaszów Mazowiecki, Polonia, 97-200
        • Research Site
      • Warsaw, Polonia, 02-781
        • Research Site
      • Guimarães, Portogallo, 4835-044
        • Research Site
      • Lisbon, Portogallo, 1649-035
        • Research Site
      • Lisbon, Portogallo, 1400-038
        • Research Site
      • Lisbon, Portogallo, 1500-650
        • Research Site
      • Lisbon, Portogallo, 1449-005
        • Research Site
      • Loures, Portogallo, 2674-514
        • Research Site
      • Porto, Portogallo, 4099-001
        • Research Site
      • Porto, Portogallo, 4200-319
        • Research Site
      • Porto, Portogallo, 4200-072
        • Research Site
      • Vila Nova de Gaia, Portogallo, 4434-502
        • Research Site
      • Blackpool, Regno Unito, FY3 8NR
        • Research Site
      • Cambridge, Regno Unito, CB2 0QQ
        • Research Site
      • London, Regno Unito, SW3 6JJ
        • Research Site
      • London, Regno Unito, WC1N 3BG
        • Research Site
      • Manchester, Regno Unito, M20 4BX
        • Research Site
      • Newport, Regno Unito, NP10 8FZ
        • Research Site
      • Nottingham, Regno Unito, NG5 1PB
        • Research Site
      • Portsmouth, Regno Unito, PO6 3LY
        • Research Site
      • Reading, Regno Unito, RG2 9LH
        • Research Site
      • Sheffield, Regno Unito, S10 2SJ
        • Research Site
      • Sutton, Regno Unito, SM2 5PT
        • Research Site
      • Taunton, Regno Unito, TA1 5DA
        • Research Site
      • Moscow, Russia, 111123
        • Research Site
      • Moscow, Russia, 143423
        • Research Site
      • Moscow, Russia, 129090
        • Research Site
      • Nizhny Novgorod, Russia, 603126
        • Research Site
      • Podolsk, Russia, 142100
        • Research Site
      • Saint Petersburg, Russia, 197758
        • Research Site
      • Saint Petersburg, Russia, 194017
        • Research Site
      • Banská Bystrica, Slovacchia, 974 01
        • Research Site
      • Bratislava, Slovacchia, 833 01
        • Research Site
      • Košice, Slovacchia, 041 91
        • Research Site
      • Michalovce, Slovacchia, 07101
        • Research Site
      • Partizánske, Slovacchia, 958 01
        • Research Site
      • A Coruña, Spagna, 15009
        • Research Site
      • Badalona, Spagna, 08003
        • Research Site
      • Barcelona, Spagna, 8035
        • Research Site
      • L'Hospitalet de Llobregat, Spagna, 08908
        • Research Site
      • Madrid, Spagna, 28041
        • Research Site
      • Madrid, Spagna, 28040
        • Research Site
      • Murcia, Spagna, 30008
        • Research Site
      • Málaga, Spagna, 29010
        • Research Site
      • Sant Joan Despí, Spagna, 08970
        • Research Site
      • Seville, Spagna, 41013
        • Research Site
      • Valencia, Spagna, 46010
        • Research Site
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85054
        • Research Site
    • Arkansas
      • Hot Springs, Arkansas, Stati Uniti, 71913
        • Research Site
      • Little Rock, Arkansas, Stati Uniti, 72205
        • Research Site
    • California
      • Long Beach, California, Stati Uniti, 90806
        • Research Site
      • San Diego, California, Stati Uniti, 92123
        • Research Site
      • Santa Rosa, California, Stati Uniti, 92805
        • Research Site
    • Colorado
      • Grand Junction, Colorado, Stati Uniti, 81501
        • Research Site
      • Lone Tree, Colorado, Stati Uniti, 80124
        • Research Site
    • Florida
      • Fort Myers, Florida, Stati Uniti, 33901
        • Research Site
      • Jacksonville, Florida, Stati Uniti, 32256
        • Research Site
      • Jacksonville, Florida, Stati Uniti, 32224
        • Research Site
      • St. Petersburg, Florida, Stati Uniti, 33705
        • Research Site
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30318
        • Research Site
      • Atlanta, Georgia, Stati Uniti, 30322
        • Research Site
      • Atlanta, Georgia, Stati Uniti, 30342
        • Research Site
    • Illinois
      • Park Ridge, Illinois, Stati Uniti, 60068
        • Research Site
    • Indiana
      • Fort Wayne, Indiana, Stati Uniti, 46804
        • Research Site
      • Indianapolis, Indiana, Stati Uniti, 46250
        • Research Site
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21202
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Research Site
      • Fairhaven, Massachusetts, Stati Uniti, 02719
        • Research Site
      • Foxborough, Massachusetts, Stati Uniti, 02035
        • Research Site
      • Milford, Massachusetts, Stati Uniti, 01757
        • Research Site
      • South Weymouth, Massachusetts, Stati Uniti, 02190
        • Research Site
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48202
        • Research Site
      • Grand Rapids, Michigan, Stati Uniti, 49503
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Research Site
    • Mississippi
      • Oxford, Mississippi, Stati Uniti, 38655
        • Research Site
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Research Site
      • St Louis, Missouri, Stati Uniti, 63110
        • Research Site
    • Montana
      • Billings, Montana, Stati Uniti, 59101
        • Research Site
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68130
        • Research Site
    • New Jersey
      • Camden, New Jersey, Stati Uniti, 08103
        • Research Site
      • Ridgewood, New Jersey, Stati Uniti, 07450
        • Research Site
    • New York
      • Brooklyn, New York, Stati Uniti, 11215
        • Research Site
      • East Syracuse, New York, Stati Uniti, 13057
        • Research Site
      • New Hyde Park, New York, Stati Uniti, 11042
        • Research Site
      • New York, New York, Stati Uniti, 10065
        • Research Site
      • New York, New York, Stati Uniti, 11355
        • Research Site
      • Shirley, New York, Stati Uniti, 11967
        • Research Site
    • North Carolina
      • Goldsboro, North Carolina, Stati Uniti, 27534
        • Research Site
    • Ohio
      • Canton, Ohio, Stati Uniti, 44710
        • Research Site
      • Cincinnati, Ohio, Stati Uniti, 45220
        • Research Site
      • Columbus, Ohio, Stati Uniti, 43219
        • Research Site
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Research Site
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
        • Research Site
      • York, Pennsylvania, Stati Uniti, 17403
        • Research Site
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29607
        • Research Site
      • West Columbia, South Carolina, Stati Uniti, 29169
        • Research Site
    • Tennessee
      • Knoxville, Tennessee, Stati Uniti, 37916
        • Research Site
      • Memphis, Tennessee, Stati Uniti, 38120
        • Research Site
      • Nashville, Tennessee, Stati Uniti, 37203
        • Research Site
    • Texas
      • Bedford, Texas, Stati Uniti, 76022
        • Research Site
      • Dallas, Texas, Stati Uniti, 75246
        • Research Site
      • Houston, Texas, Stati Uniti, 77030
        • Research Site
      • Houston, Texas, Stati Uniti, 77024
        • Research Site
      • Longview, Texas, Stati Uniti, 75601
        • Research Site
      • San Antonio, Texas, Stati Uniti, 78240
        • Research Site
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84106
        • Research Site
    • Virginia
      • Midlothian, Virginia, Stati Uniti, 23114
        • Research Site
      • Norfolk, Virginia, Stati Uniti, 23502
        • Research Site
    • Washington
      • Tacoma, Washington, Stati Uniti, 98405
        • Research Site
    • Wisconsin
      • Waukesha, Wisconsin, Stati Uniti, 53226
        • Research Site
      • Bern, Svizzera, CH-3010
        • Research Site
      • Chur, Svizzera, CH-7000
        • Research Site
      • Winterthur, Svizzera, 8401
        • Research Site
      • Kaohsiung City, Taiwan, 833
        • Research Site
      • Taichung, Taiwan, 40705
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Tainan, Taiwan, 710
        • Research Site
      • Taipei, Taiwan, 100
        • Research Site
      • Taipei, Taiwan
        • Research Site
      • Taipei, Taiwan, 11490
        • Research Site
      • Taipei, Taiwan, 23561
        • Research Site
      • Taipei, Taiwan, 11259
        • Research Site
      • Taipei, Taiwan, 110
        • Research Site
      • Taoyuan, Taiwan, 333
        • Research Site
      • Adana, Turchia (Türkiye), 01120
        • Research Site
      • Ankara, Turchia (Türkiye), 06100
        • Research Site
      • Ankara, Turchia (Türkiye), 06520
        • Research Site
      • Ankara, Turchia (Türkiye), 06010
        • Research Site
      • Ankara, Turchia (Türkiye), 06340
        • Research Site
      • Cordaleo, Turchia (Türkiye), 35575
        • Research Site
      • Izmir, Turchia (Türkiye), 35100
        • Research Site
      • Izmir, Turchia (Türkiye), 35360
        • Research Site
      • Kadıkoy/Istanbul, Turchia (Türkiye), 34722
        • Research Site
      • Kayseri, Turchia (Türkiye), 38039
        • Research Site
      • Budapest, Ungheria, 1122
        • Research Site
      • Budapest, Ungheria, 1062
        • Research Site
      • Miskolc, Ungheria, 3526
        • Research Site
      • Szekszárd, Ungheria, 7100
        • Research Site
      • Szolnok, Ungheria, 5000
        • Research Site
      • Zalaegerszeg, Ungheria, 8900
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 130 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

INCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:

  • Have advanced breast cancer that is not able to be treated with surgery or radiation;
  • Have an ESR1 mutation in their cancer;
  • Have breast cancer that is HR-positive and HER2-negative;
  • Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
  • Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
  • Are able to do their daily activities;
  • Are at least 18.

Full list of inclusion criteria:

  • Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
  • Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
  • Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
  • Eastern Cooperative Oncology Group performance status of 0 or 1;
  • ESR1m detected by central testing of ctDNA with Guardant360® CDx;
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
  • Adequate organ and marrow function.

EXCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:

  • Had certain types of tumors in the past that may come back;
  • Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
  • Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.

Full list of exclusion criteria:

  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
  • Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
  • Patient with known or family history of severe heart disease;
  • Previous treatment with AZD9833, investigational SERDs or fulvestrant;
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
  • Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: AZD9833 + palbociclib, abemaciclib or ribociclib

The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)

Dosage formulation: AZD9833 tablets will be administered orally

Dosage formulation: anastrozole placebo tablets will be administrated orally.

Dosage formulation: letrozole placebo tablets will be administered orally.

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

Comparatore attivo: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib

The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

Dosage formulation: AZD9833 placebo tablets will be administrated orally.

Dosage formulation: anastrozole tablets will be administered orally.

Dosage formulation: letrozole tablets will be administered orally.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Lasso di tempo: From randomization until the earlier of the progression event or death (approximately 2 years)

PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.

From randomization until the earlier of the progression event or death (approximately 2 years)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival 2 (PFS2)
Lasso di tempo: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)

PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
Overall survival (OS)
Lasso di tempo: From randomization until the date of death due to any cause (approximately 5 years)

The OS is defined as the time from randomization to death due to any cause.

From randomization until the date of death due to any cause (approximately 5 years)
Chemotherapy free survival
Lasso di tempo: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)

Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.

From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Lasso di tempo: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)

ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1.

From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
Clinical benefit rate at 24 weeks (CBR24)
Lasso di tempo: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)

CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment)

At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
Change from baseline in EORTC QLQ-C30 scale scores
Lasso di tempo: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Change from baseline in EORTC QLQ-BR23 scale scores
Lasso di tempo: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Plasma concentration of AZD9833 at specified timepoints
Lasso di tempo: on Day 15 for each patient

To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.

on Day 15 for each patient

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 giugno 2021

Completamento primario (Effettivo)

30 giugno 2025

Completamento dello studio (Stimato)

1 settembre 2028

Date di iscrizione allo studio

Primo inviato

30 giugno 2021

Primo inviato che soddisfa i criteri di controllo qualità

14 luglio 2021

Primo Inserito (Effettivo)

16 luglio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi